Neuland Laboratories Share Price

Neuland Laboratories shares saw a significant jump following a strong Q4 performance. The company reported a massive increase in profit and revenue year-on-year. This robust financial result was driven by strong business momentum across key segments. The company is also investing in future growth through strategic initiatives.

• Economic Times
• 1 month ago

Conference Call with Neuland Laboratories Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 month ago

Pharmaceuticals company Neuland Laboratories announced Q4FY26 & FY26 results Consolidated Financial Highlights: Quarterly Revenue: Revenue from operations for Q4FY26 stood at Rs 77,625.03 lakh, representing a growth of 76.54% QoQ from Rs 43,970.93 lakh in Q3FY26 and a significant increase of 136.40% YoY compared to Rs 32,836.00 lakh in Q4FY25. Quarterly Total Income: Total income for Q4FY26 reached Rs 78,870.85 lakh, up 76.14% QoQ from Rs 44,776.17 lakh and up 134.86% YoY from Rs 33,582.43 lakh in Q4FY25. Quarterly Profit: Profit after tax (PAT) for Q4FY26 was Rs 21,267.26 lakh, reflecting a massive growth of 424.18% QoQ compared to Rs 4,057.19 lakh in Q3FY26 and a 664.85% increase YoY from Rs 2,780.59 lakh in Q4FY25. Annual Revenue: For FY26, revenue from operations reached Rs 2,02,298.54 lakh, marking a growth of 36.98% over Rs 1,47,683.73 lakh in FY25. Annual Total Income: Annual total income stood at Rs 2,05,315.16 lakh for FY26, compared to Rs 1,49,734.66 lakh in the previous year, showing an increase of 37.12% YoY. Annual Profit: Consolidated profit after tax for FY26 reached Rs 36,399.84 lakh, reflecting a growth of 39.94% YoY from Rs 26,010.81 lakh in FY25. Total Comprehensive Income: The group reported an annual Total Comprehensive Income of Rs 36,506.25 lakh for FY26, compared to Rs 26,006.33 lakh in FY25. Standalone Financial Highlights: Quarterly Revenue: Revenue from operations for Q4FY26 reached Rs 77,625.03 lakh, up 76.54% QoQ from Rs 43,970.93 lakh in Q3FY26 and up 136.40% YoY from Rs 32,836.00 lakh in Q4FY25. Quarterly Total Income: Total income for the quarter stood at Rs 78,870.72 lakh, an increase of 76.14% QoQ from Rs 44,776.17 lakh and an increase of 134.86% YoY from Rs 33,582.38 lakh. Quarterly Profit: Standalone profit after tax for Q4FY26 was Rs 21,252.31 lakh, reflecting a growth of 425.85% QoQ from Rs 4,041.55 lakh and a significant 666.30% increase YoY from Rs 2,773.39 lakh in Q4FY25. Annual Revenue: Annual standalone revenue from operations for FY26 was Rs 2,02,298.54 lakh, a growth of 36.98% YoY compared to Rs 1,47,683.73 lakh in FY25. Annual Profit: Standalone profit For FY26 reached Rs 36,310.50 lakh, representing a growth of 39.97% YoY from Rs 25,942.54 lakh in FY25. Business Highlights: Capacity Expansion: The Board approved an enhancement of capacity at Unit 1 located at Bonthapally Village, Sangareddy District, Telangana. The project involves a proposed capacity addition of 120.5 KL with an estimated investment of Rs 143.4 crore (including GST) to be completed within 12 to 18 months. Segment Performance: The Group has only one reportable segment, namely "manufacture of active pharmaceutical ingredients and allied services." For FY26, geography-wise revenue was distributed as follows: USA and North America at Rs 71,345.10 lakh, Europe at Rs 67,544.32 lakh, India at Rs 48,409.19 lakh, and Rest of the world at Rs 14,999.93 lakh. Dividend Recommendation: The Board of Directors recommended a final dividend of Rs 34/- (340%) per equity share of face value Rs 10 each for FY26. Board Appointment: Dr. Mauricio Futran was appointed as an Additional Director in the category of Non-Executive Non-Independent Director effective May 12, 2026. Asset Transfer: During the previous year, the company fully transferred an investment property located in Hyderabad through a perpetual lease, which resulted in a total exceptional profit of Rs 7,640.36 lakh. Subsidiary Performance: The results include the audited financial results of two subsidiaries: Neuland Laboratories K.K., Japan, and Neuland Laboratories Inc., USA. Together they reflect total assets of Rs 1,147.50 lakh as at March 31, 2026, and total revenue of Rs 2,160.07 lakh for the year. Saharsh Davuluri, Chief Executive Officer & Managing Director, Neuland Laboratories, said “We are pleased with the fact that we have ended FY26 on a strong note in line with our original expectations. There is good business visibility in the short to medium term anchored by commercial and near-commercial molecules. Our focus on execution discipline, customer satisfaction, and protection of business fundamentals is central to ensuring this phase of growth. At the same time, we are laying the groundwork for growth beyond this horizon. Key elements of this foundation are the investments in Peptide Manufacturing as well as the new R&D; Centre, which are proceeding according to plan. Our Business Development strategy is aligned to the investments and is focused on bringing in the right kind of projects that support high quality, sustainable growth.” Result PDF

• Trendlyne
• 1 month 1 week ago